This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of the BIOTIME SARS-CoV-2 IgG/IgM Rapid Qualitative Test.

The BIOTIME SARS-CoV-2 IgG/IgM Rapid Qualitative Test is authorized for the detection and differentiation of IgG and IgM antibodies to SARS-CoV-2 in human serum, plasma (potassium EDTA), or potassium EDTA venous whole blood.

All individuals whose specimens are tested with this assay will receive the Fact Sheet for Recipients: BIOTIME SARS-CoV-2 IgG/IgM Rapid Qualitative Test.

What are the symptoms of COVID-19?
Many individuals with confirmed COVID-19 have developed fever and/or symptoms of acute respiratory illness (e.g., cough, difficulty breathing). The current information available to characterize the spectrum of clinical illness associated with COVID-19 suggests that symptoms include cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, headache, sore throat or new loss of taste or smell. Based on what is known about the virus that causes COVID-19, signs and symptoms may appear any time from 2 to 14 days after exposure to the virus. Based on preliminary data, the median incubation period is approximately 5 days, but may range 2-14 days.

Public health officials have identified cases of COVID-19 infection throughout the world, including the United States, which poses risks for public health. Please check the CDC webpage for the most up to date information.

What do I need to know about COVID-19 antibody testing?
Current information on COVID-19 for healthcare providers is available at CDC’s webpage, Information for Healthcare Professionals (see links provided in “Where can I go for updates and more information” section).

Specimens should be collected with appropriate infection control precautions. Current guidance for COVID-19 infection control precautions are available at the CDC’s website (see links provided in “Where can I go for updates and more information” section).

Use appropriate personal protective equipment when collecting and handling specimens from individuals suspected of having COVID-19 as outlined in the CDC Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19). These specimens are only shipped for analysis to laboratories designated by CDC.

Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling 1-800-FDA-1088
as qualified for analysis. For additional information, refer to CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19) (see links provided in “Where can I go for updates and more information” section).

There are no approved available alternative tests. FDA has issued EUAs for other antibody tests that can be found at https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#2019-ncov.

What does it mean if the specimen tests positive for antibodies against the virus that causes COVID-19? A positive test result with the BIOTIME SARS-CoV-2 IgG/IgM Rapid Qualitative Test indicates that antibodies against SARS-CoV-2 were detected, and the individual has potentially been exposed to SARS-CoV-2.

Antibodies to SARS-CoV-2 are generally detectable in blood several days following infection. Individuals may have detectable virus present for several weeks following seroconversion. If antibodies are present it often indicates a past infection but does not exclude recently infected individuals who are still contagious. **It is unknown how long antibodies to SARS-CoV-2 will remain present in the body after infection and if they confer immunity to infection. Incorrect assumptions of immunity may lead to premature discontinuation of physical distancing requirements and increase the risk of infection for individuals, their households and the public.**

False positive results may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

The BIOTIME SARS-CoV-2 IgG/IgM Rapid Qualitative Test has been designed to minimize the likelihood of false positive test results. However, in the event of a false positive result, risks to individuals could include the following: risk of infection by exposure to persons with active COVID-19, a recommendation for isolation of the individual, monitoring of household or other close contacts for symptoms, isolation that might limit contact with family or friends and may increase contact with other potentially COVID-19 individuals, limits in the ability to work, the delayed diagnosis and treatment for the true infection causing the symptoms or other unintended adverse effects. **Due to the risk of false positive results, confirmation of positive results should be considered – using a second, different antibody assay that detects the same type of antibodies.**

Laboratory test results should always be considered in the context of clinical observations and epidemiological data in making patient management decisions.

All laboratories using this test must follow the standard confirmatory testing and reporting guidelines according to their appropriate public health authorities.

What does it mean if the specimen tests negative for antibodies against the virus that causes COVID-19? A negative test result for this test means that SARS-CoV-2 specific antibodies were not present in the specimen above the limit of detection of the assay. However, individuals tested early after infection may not have detectable antibodies despite active infection; in addition, it is not certain that all infected individuals will develop a detectable antibody response to SARS-CoV-2 infection. A negative result should not be used to rule out COVID-19 infection. **Direct testing of SARS-CoV-2 should be performed if acute infection is suspected.**

The absolute sensitivity of the BIOTIME SARS-CoV-2 IgG/IgM Rapid Qualitative Test is unknown.

Risks to an individual resulting from a false negative result include: restriction of activities deemed acceptable for individuals with evidence of an antibody response to SARS-CoV-2, lack of monitoring of infected individuals and their household or other close contacts for symptoms resulting in increased risk of spread of COVID-19 within the community, or other unintended adverse events.

**What is an EUA?** The United States FDA has made this test available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is

---

**Report Adverse events**, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling 1-800-FDA-1088
supported by the Secretary of Health and Human Service’s (HHS’s) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19.

An IVD made available under an EUA has not undergone the same type of review as an FDA-approved or cleared IVD. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives, and based on the totality of scientific evidence available, it is reasonable to believe that this IVD may be effective.

The EUA for this test is in effect for the duration of the COVID-19 declaration justifying emergency use of IVDs, unless terminated or revoked (after which the test may no longer be used).

Where can I go for updates and more information?

**CDC webpages:**
- General: [https://www.cdc.gov/COVID19](https://www.cdc.gov/COVID19)

**FDA webpages:**
- General: [www.fda.gov/novelcoronavirus](http://www.fda.gov/novelcoronavirus)
- EUAs:(includes links to recipient fact sheet and manufacturer’s instructions) [https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations)

**Xiamen Biotime Biotechnology Co., Ltd.:**
3F/4F, No.188, Pingcheng S. Road
Haicang District, Xiamen, Fujian
361026, P. R. China

E-mail: baotai@xmbtsw.com
Website: [www.biotime.cn](http://www.biotime.cn)